

CSD/BSE&NSE/BM/2025-26
August 13, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Press Release

Please find annexed press release on the unaudited financial results of the Company for the quarter ended June 30, 2025.

This is for your information and record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Encl: as above

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com





Cohance Lifesciences Announces Q1FY26 Results

Revenue up 13% YoY; niche technology share crosses 20% with significant traction in ADC payload-linkers, oligonucleotides, and late-phase high-containment APIs.

Hyderabad/Mumbai, August 13, 2025

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited), a leading global CDMO (Contract Development and Manufacturing Organization), today announced its financial results for the first quarter ended June 30, 2025. This represented the Company's first full quarter operating as Cohance Lifesciences.

Q1FY26 Financial Performance

The Company reported revenue of ₹5,493 million, up 13% year-on-year. Excluding the temporary impact of inventory destocking in Pharma CDMO, Q1FY26 revenue growth exceeds 25%. Gross margins expanded to 73.0% from 68.4% in Q1FY25, driven by a richer mix of niche technologies and contributions from recent acquisitions. Adjusted EBITDA was ₹1,314 million with a margin of 23.9%, in line with planned investments in high-value modalities, talent, and the integration of NJ Bio and Sapala.

Niche technology revenues accounted for over 20% of total sales compared to the mid-teens in FY25 and are on track to reach the mid-20s by the end of FY26. Pharma CDMO revenue grew over 30% excluding de-stocking. Specialty Chemicals rose 28% on AgChem recovery and new projects, while API+ grew 19% on strong commercial execution and the ramp-up of new launches.

Key Business Highlights of Q1FY26

A USD 10 million bioconjugation cGMP suite is under construction at NJ Bio's Princeton facility, and a ₹230 million oligonucleotide building block facility in Hyderabad, with up to 700 kg/year GMP capacity, remains on track for end-CY25 operational readiness.

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

The Company received a significant early-phase integrated payload-linker synthesis and bioconjugation order from an existing partner in the U.S. in our subsidiary NJ Blo. Company has simultaneously initiated development of a new OEB6 high-containment dedicated block for a major U.S.-based large innovator's customized payload program in India.

The Company secured a life cycle management contract for a branded API with a leading innovator. From our phase three pipeline, our partner has received USFDA approval for another small molecule program with Priority Review and Breakthrough Therapy Designation.

Cohance added four new large global innovators to its customer base and continued pipeline expansion across high-containment APIs, late-phase programs, and oligonucleotide process development.

Strategic Updates

Appointed Mr. Yann D'Hervé as CEO of CDMO business. Yann brings nearly three decades of global leadership, including ~15 years in CDMO-specific roles. His experience spans P&L management, global commercial leadership, and scale-up of complex, modality-driven platforms.

The Company has established the Cohance External Advisory Board (EAB) as part of its strategic focus on customer-centric growth. The EAB comprises five distinguished global pharma leaders-each bringing deep operational and strategic expertise from leading innovator companies-to guide Cohance's scale-up and differentiation across high-growth modalities.

Mr. Vivek Sharma, Executive Chairman, said: *"Q1FY26 has been an important start to the year, with progress not just in execution but in strengthening the foundation we have built. Our growing presence in niche modalities like ADCs and oligonucleotides, combined with a deepening global customer base, positions Cohance for accelerated growth. With strengthened leadership and the guidance of our External Advisory Board, we remain committed to becoming a global technology-led CDMO, delivering long-term value for all stakeholders."*

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

About Cohance Lifesciences

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. Leveraging a combined platform with state-of-the-art facilities in India and the U.S., Cohance delivers integrated solutions from early development to commercial supply for leading global pharma companies. In FY25, revenue was INR 26,103 million (~USD 313 million) with 33.6% EBITDA margins, with the CDMO business-driven largely by its commercial partnerships with global innovators.

-ENDS-

For more information, please contact: www.cohance.com

Cyndrella Carvalho, Head - Investor Relations,

Cohance Lifesciences Limited

Tel: 040 2354 3311

Email: cyndrella.carvalho@cohance.com

Gavin Desa / Rishab Barar

CDR India

Tel: +91 98206 37649/ +91 77770 35061

Email: gavin@cdr-india.com

rishab@cdr-india.com

The banner features a yellow background with the Cohance logo in the top right corner. On the left, the text reads "Cohance.com Is Now Live" in large, bold, black font, followed by "A unified digital gateway showcasing our integrated CDMO capabilities across pharma and specialty chemicals" in a smaller black font. On the right, there is a computer monitor displaying the Cohance website. The website header includes "Cohance" and a navigation menu with items: "About Us", "Small Molecule APIs", "ADCs", "Nucleic Acid Chemistry", "Gene & APIs", "Specialty Chemicals", and "Investors". The main content area of the website shows a laboratory setting with two workers in white lab coats and hard hats. Text on the website reads "Multi-Modality Expertise. One Trusted CDMO Partner." and "A global CDMO platform specialized in ADCs, Nucleic Acid Chemistry, and Small Molecules." Below the banner, there is a white circular graphic on the left and the text "Collaborate. Enhance. Deliver. Visit: www.cohance.com" on the right.

Cohance Lifesciences Limited

(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.

Tel: +91 40 2354 9414 / 3311

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.

Tel: +91 22 6153 9999